Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

The move will provide funds to advance ETX101, a gene therapy the company is developing for SCN1A-positive Dravet syndrome, among other programs.

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

EAU CLAIRE, Wis. (WEAU) - A car crashed into Prevail Bank on Fairfax Street by HyVee Friday evening. Our photojournalist on scene saw the car almost completely in the building with a tow truck pulling ...

Keyshawn Davis believes the experience that David Benavidez will lead to him defeating the slightly younger 11-fight professional David Morrell this Saturday night at the T-Mobile Arena in Las ...

Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of patients with chronic cough in ...

Emo, short for "emotional hardcore," emerged in the mid-1980s. It evolved into a cornucopia of styles, from indie rock to pop-punk. Pioneers like Rites of Spring and Embrace sowed the seeds, while ...

LOS ANGELES, CALIFORNIA - AUGUST 20: The Target logo is displayed at a Target store on August 20, 2024 in Los Angeles, California. Target is set to release its second quarter earnings report ...

The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

Shares of Summit Therapeutics (NASDAQ: SMMT) had jumped 14.3% at 11:31 a.m. ET on Tuesday. The nice gain came after reports that H.C. Wainwright analyst Mitchell Kapoor maintained a "buy" rating ...

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.